• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏液样脂肪肉瘤的诊断与治疗:组织学很重要。

Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.

机构信息

Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, Box 8076 660 S. Euclid Avenue, St. Louis, MO, 63110, USA.

Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA.

出版信息

Curr Treat Options Oncol. 2018 Oct 25;19(12):64. doi: 10.1007/s11864-018-0590-5.

DOI:10.1007/s11864-018-0590-5
PMID:30362022
Abstract

Sarcomas are a heterogeneous group of rare malignancies that arise from mesenchymal cells and can occur anywhere in the body. Herein, the focus will be on one subtype of sarcoma that arises from adipocytic tissue, liposarcoma. Specifically, the review will focus on one type of liposarcoma, myxoid liposarcoma. Given the rarity of this tumor, it is imperative that these patients are treated at a sarcoma center, where a multidisciplinary approach incorporates all the modalities available including clinical trials. As the understanding of the biology of myxoid liposarcomas progresses, more targeted therapies are being developed that will lead to better tolerated treatments and improved survival for patients. In this review, we will be discussing the pathophysiology, clinical presentation, diagnostic workup, and available treatment options including surgery, radiation, chemotherapy, and clinical trials.

摘要

肉瘤是一组源自间叶细胞的罕见恶性肿瘤,可发生在身体的任何部位。本文将重点介绍一种源自脂肪组织的肉瘤,即脂肪肉瘤。具体而言,本综述将聚焦于一种脂肪肉瘤,黏液样脂肪肉瘤。鉴于这种肿瘤的罕见性,至关重要的是,这些患者在肉瘤中心接受治疗,肉瘤中心采用多学科方法结合所有可用的治疗手段,包括临床试验。随着对黏液样脂肪肉瘤生物学的理解不断深入,正在开发更具针对性的治疗方法,这将导致更好耐受的治疗方法和提高患者的生存率。在本综述中,我们将讨论黏液样脂肪肉瘤的病理生理学、临床表现、诊断方法以及手术、放疗、化疗和临床试验等可用的治疗选择。

相似文献

1
Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.黏液样脂肪肉瘤的诊断与治疗:组织学很重要。
Curr Treat Options Oncol. 2018 Oct 25;19(12):64. doi: 10.1007/s11864-018-0590-5.
2
A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.探讨 trabectedin 在高级黏液样脂肪肉瘤中的现有证据的全面综述。
Cancer Treat Rev. 2019 Jan;72:37-44. doi: 10.1016/j.ctrv.2018.11.003. Epub 2018 Nov 15.
3
Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.脂肪肉瘤的药物治疗:当前的最新进展和新兴的系统治疗方法。
Expert Opin Pharmacother. 2019 Aug;20(12):1503-1515. doi: 10.1080/14656566.2019.1618271. Epub 2019 May 28.
4
[Subcutaneous myxoid liposarcoma].[皮下黏液样脂肪肉瘤]
Pan Afr Med J. 2017 Mar 21;26:162. doi: 10.11604/pamj.2017.26.162.8494. eCollection 2017.
5
Myxoid Liposarcomas: Systemic Treatment Options.黏液样脂肪肉瘤:全身治疗选择
Curr Treat Options Oncol. 2023 Apr;24(4):274-291. doi: 10.1007/s11864-023-01057-4. Epub 2023 Feb 28.
6
Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.年轻患者的脂肪肉瘤:一项针对82例发生于22岁以下患者的研究。
Am J Surg Pathol. 2009 May;33(5):645-58. doi: 10.1097/PAS.0b013e3181963c9c.
7
Liposarcoma: Multimodality Management and Future Targeted Therapies.脂肪肉瘤:多模态管理与未来靶向治疗
Surg Oncol Clin N Am. 2016 Oct;25(4):761-73. doi: 10.1016/j.soc.2016.05.007. Epub 2016 Jul 30.
8
Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.曲贝替定在黏液样脂肪肉瘤中的抗血管生成活性:宿主组织金属蛋白酶抑制因子-1和组织金属蛋白酶抑制因子-2以及肿瘤血小板反应蛋白-1的参与
Int J Cancer. 2015 Feb 1;136(3):721-9. doi: 10.1002/ijc.29023. Epub 2014 Jun 19.
9
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.晚期脂肪肉瘤已确立的及实验性全身治疗方案
Oncol Res Treat. 2022;45(9):525-543. doi: 10.1159/000524939. Epub 2022 May 24.
10
Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy.在接受新辅助阿霉素和异环磷酰胺治疗以及术前放射治疗的黏液样脂肪肉瘤中,可以看到广泛的脂肪细胞成熟。
Clin Sarcoma Res. 2012 Dec 29;2(1):25. doi: 10.1186/2045-3329-2-25.

引用本文的文献

1
Advances in F-fluorodeoxyglucose positron emission tomography/computed tomography for soft tissue sarcomas.F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在软组织肉瘤中的进展
World J Radiol. 2025 Jul 28;17(7):106427. doi: 10.4329/wjr.v17.i7.106427.
2
Myxolipoma of the Popliteal Fossa: A Rare Tumor Case Report.腘窝黏液脂肪瘤:1例罕见肿瘤病例报告
Reports (MDPI). 2024 Jul 25;7(3):58. doi: 10.3390/reports7030058.
3
Giant transverse colonic mesenteric mucinous liposarcoma combined with rectal cancer and aortic coarctation: A case report and review of literature.

本文引用的文献

1
NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.NY-ESO-1:一种用于肉瘤免疫治疗和诊断的有前景的癌睾丸抗原。
Chin Clin Oncol. 2018 Aug;7(4):44. doi: 10.21037/cco.2018.08.11.
2
Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies.转移性软组织肉瘤:治疗与新药物疗法综述
P T. 2018 Jul;43(7):410-429.
3
Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.采用联合 DNA、mRNA 和蛋白质分析鉴定黏液样脂肪肉瘤中调节细胞增殖和 FUS-DDIT3 表达的抑制剂。
巨大横结肠系膜黏液性脂肪肉瘤合并直肠癌及主动脉缩窄:一例报告并文献复习
World J Gastrointest Surg. 2025 Jun 27;17(6):107866. doi: 10.4240/wjgs.v17.i6.107866.
4
Magnetic resonance imaging assessing the correlation of components and prognosis in myxoid liposarcoma.磁共振成像评估黏液样脂肪肉瘤各成分与预后的相关性。
Acta Radiol. 2025 Sep;66(9):999-1007. doi: 10.1177/02841851251337861. Epub 2025 May 21.
5
Diagnosis and Treatment of Myxoid Liposarcoma.黏液样脂肪肉瘤的诊断与治疗。
Curr Treat Options Oncol. 2024 Oct;25(10):1289-1296. doi: 10.1007/s11864-024-01262-9. Epub 2024 Sep 20.
6
Myxoid Liposarcomas of the Thigh: Pre-Operative Presentation, Clinical Outcomes, and Functional Results of Surgical Treatment.大腿黏液样脂肪肉瘤:术前表现、临床结果及手术治疗的功能结果
Healthcare (Basel). 2024 Aug 28;12(17):1718. doi: 10.3390/healthcare12171718.
7
Mandibular Myxoid Liposarcoma: a Case Study.下颌黏液样脂肪肉瘤:病例研究
Indian J Surg Oncol. 2024 Mar;15(Suppl 1):19-21. doi: 10.1007/s13193-023-01705-z. Epub 2023 Jan 21.
8
The usefulness of immunohistochemistry for phosphohistone H3 as a prognostic factor in myxoid liposarcoma.免疫组织化学检测磷酸化组蛋白 H3 在黏液样脂肪肉瘤中作为预后因素的有用性。
Sci Rep. 2023 Mar 23;13(1):4733. doi: 10.1038/s41598-023-31896-y.
9
Myxoid Liposarcomas: Systemic Treatment Options.黏液样脂肪肉瘤:全身治疗选择
Curr Treat Options Oncol. 2023 Apr;24(4):274-291. doi: 10.1007/s11864-023-01057-4. Epub 2023 Feb 28.
10
Case report: Metastatic myxoid liposarcoma arising from the right atrium extends as cardiac tamponade-A rare case of atrial oncology.病例报告:起源于右心房的转移性黏液样脂肪肉瘤扩展导致心脏压塞——一例罕见的心房肿瘤病例
Front Cardiovasc Med. 2023 Jan 26;9:1046436. doi: 10.3389/fcvm.2022.1046436. eCollection 2022.
Lab Invest. 2018 Jul;98(7):957-967. doi: 10.1038/s41374-018-0046-3. Epub 2018 Mar 27.
4
Advances in the treatment of soft tissue sarcoma: focus on eribulin.软组织肉瘤治疗进展:聚焦于艾瑞布林
Cancer Manag Res. 2018 Feb 1;10:207-216. doi: 10.2147/CMAR.S143019. eCollection 2018.
5
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
6
Clinical and Molecular Spectrum of Liposarcoma.脂肪肉瘤的临床与分子谱。
J Clin Oncol. 2018 Jan 10;36(2):151-159. doi: 10.1200/JCO.2017.74.9598. Epub 2017 Dec 8.
7
FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.FUS-CHOP 通过 SRC/FAK/RHO/ROCK 依赖性途径促进黏液样脂肪肉瘤的侵袭。
Neoplasia. 2018 Jan;20(1):44-56. doi: 10.1016/j.neo.2017.11.004. Epub 2017 Nov 28.
8
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.在一项埃立布林对比达卡巴嗪的随机 III 期研究的亚组分析中,晚期脂肪肉瘤患者中观察到埃立布林的活性。
J Clin Oncol. 2017 Oct 20;35(30):3433-3439. doi: 10.1200/JCO.2016.71.6605. Epub 2017 Aug 30.
9
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.FDA 批准概要:多柔比星含药方案治疗失败的不可切除或转移性脂肪肉瘤或平滑肌肉瘤的 trabectedin。
Clin Cancer Res. 2017 Dec 15;23(24):7448-7453. doi: 10.1158/1078-0432.CCR-17-0898. Epub 2017 Aug 3.
10
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.基于组织学分型的新辅助化疗对比标准化疗用于高危软组织肉瘤患者(ISG-STS 1001):一项国际、开放标签、随机、对照、III 期、多中心试验
Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9.